| Dr Michael Alberts, MD | |
|
1303 E Herndon Ave, Fresno, CA 93720-3309 | |
| (559) 450-3205 | |
| Not Available |
| Full Name | Dr Michael Alberts |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 28 Years |
| Location | 1303 E Herndon Ave, Fresno, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366483943 | NPI | - | NPPES |
| A63798 | Other | BC OF CA | |
| A63798 | Other | COUNTY OF FRESNO | |
| 00A637980 | Other | BS OF CA | |
| 00A637980 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | A63798 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Mary's Medical Center | San francisco, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cep America - California | 6103739131 | 954 |
News Archive
Within seconds after an infected mosquito bites, the malaria parasite navigates the host skin and blood vessels to invade the liver, where it will stay embedded until thousands of infected cells burst into the bloodstream, launching malaria's deadly blood-stage infection.
"The U.S. government on Thursday released a new policy that will require federal agencies to systematically review the potential risks associated with federally funded studies involving 15 'high consequence' pathogens and toxins, including the H5N1 avian influenza virus," Science Insider reports.
Eli Lilly and Company today announced it will begin enrolling patients in a second Phase III study of LY450139, a gamma-secretase inhibitor being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer's disease.
KYTHERA Biopharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application that claims synthetic deoxycholic acid or pharmaceutically acceptable salts thereof, including the synthetic form that is used in ATX-101, a potential first-in-class, injectable drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin."
› Verified 1 days ago
| Entity Name | Cep America - California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023063542 PECOS PAC ID: 6103739131 Enrollment ID: O20031106000520 |
News Archive
Within seconds after an infected mosquito bites, the malaria parasite navigates the host skin and blood vessels to invade the liver, where it will stay embedded until thousands of infected cells burst into the bloodstream, launching malaria's deadly blood-stage infection.
"The U.S. government on Thursday released a new policy that will require federal agencies to systematically review the potential risks associated with federally funded studies involving 15 'high consequence' pathogens and toxins, including the H5N1 avian influenza virus," Science Insider reports.
Eli Lilly and Company today announced it will begin enrolling patients in a second Phase III study of LY450139, a gamma-secretase inhibitor being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer's disease.
KYTHERA Biopharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application that claims synthetic deoxycholic acid or pharmaceutically acceptable salts thereof, including the synthetic form that is used in ATX-101, a potential first-in-class, injectable drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin."
› Verified 1 days ago
| Entity Name | Saint Agnes Medical Center |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1205845567 PECOS PAC ID: 3971409335 Enrollment ID: O20070824000478 |
News Archive
Within seconds after an infected mosquito bites, the malaria parasite navigates the host skin and blood vessels to invade the liver, where it will stay embedded until thousands of infected cells burst into the bloodstream, launching malaria's deadly blood-stage infection.
"The U.S. government on Thursday released a new policy that will require federal agencies to systematically review the potential risks associated with federally funded studies involving 15 'high consequence' pathogens and toxins, including the H5N1 avian influenza virus," Science Insider reports.
Eli Lilly and Company today announced it will begin enrolling patients in a second Phase III study of LY450139, a gamma-secretase inhibitor being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer's disease.
KYTHERA Biopharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application that claims synthetic deoxycholic acid or pharmaceutically acceptable salts thereof, including the synthetic form that is used in ATX-101, a potential first-in-class, injectable drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin."
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Alberts, MD Po Box 28951, Fresno, CA 93729-8951 Ph: (888) 398-1370 | Dr Michael Alberts, MD 1303 E Herndon Ave, Fresno, CA 93720-3309 Ph: (559) 450-3205 |
News Archive
Within seconds after an infected mosquito bites, the malaria parasite navigates the host skin and blood vessels to invade the liver, where it will stay embedded until thousands of infected cells burst into the bloodstream, launching malaria's deadly blood-stage infection.
"The U.S. government on Thursday released a new policy that will require federal agencies to systematically review the potential risks associated with federally funded studies involving 15 'high consequence' pathogens and toxins, including the H5N1 avian influenza virus," Science Insider reports.
Eli Lilly and Company today announced it will begin enrolling patients in a second Phase III study of LY450139, a gamma-secretase inhibitor being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer's disease.
KYTHERA Biopharmaceuticals, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent application that claims synthetic deoxycholic acid or pharmaceutically acceptable salts thereof, including the synthetic form that is used in ATX-101, a potential first-in-class, injectable drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin."
› Verified 1 days ago
Michelle Lea Storkan, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2823 Fresno St, Fresno, CA 93721 Phone: 559-499-6440 | |
Harminder S Longia, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2615 E Clinton Ave, Fresno, CA 93703 Phone: 559-225-6100 | |
Dr. Jessie Werner, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2823 Fresno St, Fresno, CA 93721 Phone: 559-499-6440 | |
Megann Forrest Young, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2823 Fresno St, Fresno, CA 93721 Phone: 559-499-6440 Fax: 559-499-6441 | |
Geoffrey R Stroh, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2823 Fresno St, Fresno, CA 93721 Phone: 559-499-6440 Fax: 559-499-6441 | |
Marc Stanley Shalit, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2823 Fresno St, Fresno, CA 93721 Phone: 559-499-6439 Fax: 559-499-6441 | |
Dr. Patil Armenian, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2823 Fresno St, Fresno, CA 93721 Phone: 559-499-6440 |